Latest Ankylosing Spondylitis news
Bimekizumab Well Tolerated, Efficacious Over Three Years in Axial Spondyloarthritis
posted July 9th
by modernClinician Editorial Team
by modernClinician Editorial Team
FDA Approves Bimzelx for Three New Indications
posted September 26th
by modernClinician Editorial Team
by modernClinician Editorial Team
Secukinumab Cuts Symptoms of Ankylosing Spondylitis
posted December 23rd
by modernClinician Editorial Team
by modernClinician Editorial Team
For patients with active ankylosing spondylitis, secukinumab is associated with reductions in symptoms at week 16, according to a study published in the Dec. 24 issue of the New England Journal of Medicine.
Editor's Recommendations
Drug Interactions Reducing Contraceptive Effectiveness Common in Epilepsy .jpg)
Most Specialty Oral Anticancer Meds for Blood Cancers Are Initially Rejected by Insurers 
1 in 3 With Lupus Take Supplements, Medications With Potential for Interactions 
Holding DMARDs at Time of COVID-19 Vaccine Not Warranted in Those With Inflammatory Arthritis Related Articles
Age-, Joint-Specific Ultrasound Reference Values Set for Healthy Joints 
2013 to 2024 Saw Decrease in Benzodiazepine Prescribing 
GLP-1 Receptor Agonists, SGLT-2is Slow Renal Function Decline in T2D With Albuminuria 
Polypharmacy of Prescription Medications Increased for U.S. Older Adults Monthly Specialist Briefings
Stay Connected
